Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

NCT02637973 is registered in ClinicalTrials.gov with The Deutsche Diabetes Forschungsgesellschaft e.V. as lead sponsor.

NCT NCT02637973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02637973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Lead sponsor
The Deutsche Diabetes Forschungsgesellschaft e.V.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2015
Completion date
August 31, 2018
Enrollment
84 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease, type 2 diabetes